KPV

Four things to know · April 15, 2026

All compounds

KPV

Lysine-Proline-Valine

KPV is a small anti-inflammatory peptide, derived from a naturally occurring hormone your body already makes.

6 studies cited

Noticed in days · Full benefit in weeks

Week 1

Most common report: decreased inflammatory symptoms.

Week 2-3

Typically reduced pain and swelling, improved energy.

Week 4

Significant improvement in target condition is commonly reported.

Week 6-8

Sustained anti-inflammatory benefits are commonly reported.

KPV is a small anti-inflammatory peptide, derived from a naturally occurring hormone your body already makes. It reduces inflammation and fights microbes without the skin-darkening side effects of the full hormone. What makes it stand out: KPV can enter cells directly and turn off inflammatory signals from the inside, which is why it keeps showing up in research on gut conditions, skin inflammation, and immune balance.

HOW IT WORKS

How it works

Most anti-inflammatory compounds work on the surface of cells. KPV is small enough to pass through the membrane and reach the nucleus, where it blocks NF-κB, one of the body's main inflammation switches. That inside-out approach is why it's being studied for conditions where inflammation is deep and persistent.

BEST FOR

Key benefits

What early research points to:

  • ·Reduces inflammation from inside the cell, not just the surface
  • ·Antimicrobial action alongside the anti-inflammatory effect
  • ·No skin pigmentation changes (unlike the full hormone it comes from)
  • ·Particularly promising for gut and skin inflammation
REGULATORY STATUS

Regulatory status

Category 2. The FDA's pharmacy compounding advisory committee is scheduled to review KPV on July 23, 2026, for potential addition to the 503A bulks list. The uses under review: wound healing and inflammatory conditions.

Journal · July 2026 PCAC

What the peptide panel is really voting on →

DOSING

Injection

most studied

The primary route for whole-body anti-inflammatory and immune-modulating effects. KPV injection delivers the peptide systemically for conditions affecting multiple areas, autoimmune support, and broad inflammation reduction.

Injection protocols

ProtocolDoseFrequency
General anti-inflammatory200-300mcgOnce daily
Active inflammation250mcgTwice daily
Autoimmune support500mcgOnce daily
Acute flare-ups500mcgTwice daily for 1 week, then reduce

Protocols are from published research literature. This is not medical advice. Dosing should be determined by a licensed clinician.

What people report

Week 1

Most common report: decreased inflammatory symptoms.

Week 2-3

Typically reduced pain and swelling, improved energy.

Week 4

Significant improvement in target condition is commonly reported.

Week 6-8

Sustained anti-inflammatory benefits are commonly reported.

What to know

  • Well-tolerated in published research, with few reported side effects
  • Well-tolerated at doses up to 500mcg injection and 1mg oral in available research
  • Reduces inflammation without immunosuppression; the immune system stays active
  • The full hormone KPV comes from (alpha-MSH) causes tanning, but KPV does not

Also available as

KEY RESEARCH · 6 PAPERS CITED

Dalmasso G et al.

Gastroenterology

2008

Read paper →

Kannengiesser K et al.

Inflammatory Bowel Diseases

2008

Read paper →

Xiao B et al.

Molecular Therapy

2017

Read paper →

Land SC

International Journal of Physiology, Pathophysiology and Pharmacology

2012

Read paper →

Viennois E et al.

Cellular and Molecular Gastroenterology and Hepatology

2016

Read paper →

Cutuli M et al.

Journal of Leukocyte Biology

2000

Read paper →

The Pep Dispatch

Follow the evidence on KPV as it evolves.

Subscribe to find out what.

Next dispatch · May 2026 · Honest frequency: a few times a month

For the people who want to feel better — not just look up symptoms.